Comment on

• A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.

  Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. Thal LJ, et al. Neurology. 1996 Dec;47(6):1389-95. doi: 10.1212/wnl.47.6.1389. Neurology. 1996. PMID: 8960716 Clinical Trial.